21 – 30 of 40
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration : a retrospective diagnostic performance study
(
- Contribution to journal › Article
-
Mark
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
(
- Contribution to journal › Scientific review
-
Mark
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
(
- Contribution to journal › Article
-
Mark
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations
(
- Contribution to journal › Article
-
Mark
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
(
- Contribution to journal › Article